These immunotherapies, which may be used for MDR-TBM, include recombinant IL-2, IL-7, IL-12, IL-15, IL-24, and IFN-γ, may enhance the immune response, improving microbicidal effects and overall management of TB and TBM. This evidence concerns the gene IFNG and meningeal tuberculosis.